Compare FLR & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLR | AMRX |
|---|---|---|
| Founded | 1912 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.4B |
| IPO Year | 2006 | 2018 |
| Metric | FLR | AMRX |
|---|---|---|
| Price | $48.40 | $21.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $59.56 | $24.29 |
| AVG Volume (30 Days) | 2.3M | ★ 3.5M |
| Earning Date | 11-06-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 157.89 |
| EPS | ★ 3.04 | 0.29 |
| Revenue | ★ $15,503,000,000.00 | N/A |
| Revenue This Year | $2.81 | $6.38 |
| Revenue Next Year | $11.01 | $9.21 |
| P/E Ratio | ★ $16.15 | $73.78 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $39.33 | $11.39 |
| 52 Week High | $58.35 | $22.07 |
| Indicator | FLR | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.36 | 57.02 |
| Support Level | $47.21 | $18.90 |
| Resistance Level | $49.85 | $21.21 |
| Average True Range (ATR) | 2.06 | 0.86 |
| MACD | 0.44 | 0.04 |
| Stochastic Oscillator | 61.18 | 71.96 |
Fluor is one of the largest global providers of engineering, procurement, construction, fabrication, operations, and maintenance services. It serves a wide range of end markets, including oil and gas, chemicals, mining, metals, and transportation. The company's business is organized into three core segments: urban solutions, mission solutions, and energy solutions. Fluor generated $15.5 billion in revenue in 2025.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.